Robert Romanelli, MD
Internal Medicine · Libertyville, ILNPI 1144208554
Payments from drug & device makers
Across 648 payments — averaging $124.57 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Genentech USA, Inc.$62K
- GE HealthCare$8K
- AstraZeneca$3K
- AbbVie$988
- Lilly USA, LLC$872
- Boehringer Ingelheim$842
- plus $5K from 28 others
What the payments were for
- Consulting fees$7,93710%
- Speaking & faculty fees$52,26365%
- Travel & lodging$7,78010%
- Food & beverage$12,71016%
- Education$330%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Genentech USA, Inc. | 94 | $62,182 |
| GE HealthCare | 1 | $7,937 |
| AstraZeneca | 119 | $2,930 |
| AbbVie(2 entities) | 64 | $988 |
| Lilly USA, LLC | 47 | $872 |
| Boehringer Ingelheim | 37 | $842 |
| Novo Nordisk | 32 | $566 |
| Amgen(2 entities) | 28 | $522 |
| Novartis | 23 | $465 |
| Johnson & Johnson(2 entities) | 30 | $456 |
| Amarin Pharma, Inc. | 19 | $388 |
| Merck | 19 | $316 |
| GSK | 18 | $310 |
| Esperion Therapeutics, Inc. | 10 | $275 |
| Pfizer | 16 | $253 |
| Kowa Pharmaceuticals America, Inc. | 25 | $201 |
| Exact Sciences | 9 | $193 |
| Idorsia Pharmaceuticals US Inc | 7 | $137 |
| Corcept Therapeutics | 5 | $119 |
| Abbott | 6 | $112 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 7 | $107 |
| Biohaven Pharmaceutical Holding Company Ltd. | 5 | $94 |
| IBSA Pharma Inc. | 5 | $83 |
| Eisai Inc. | 5 | $79 |
| Teva Pharmaceuticals USA, Inc. | 3 | $62 |
| Medicure Pharma Inc. | 3 | $52 |
| Biohaven Pharmaceuticals, Inc. | 2 | $44 |
| Sanofi-aventis U.S. LLC | 3 | $40 |
| Melinta Therapeutics, LLC | 1 | $24 |
| Vistapharm, Inc. | 1 | $19 |
| Phathom Pharmaceuticals, Inc. | 1 | $19 |
| Metuchen Pharmaceuticals | 1 | $16 |
| Inspire Medical Systems, Inc. | 1 | $15 |
| Bardy Diagnostics, Inc. | 1 | $7 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$80,723 in reported general payments places this provider in the 95th percentile of 5,182 internal medicine providers in Illinois.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| MounjaroTirzepatide | 49 | $50,769 |
| OzempicSemaglutide | 41 | $46,953 |
| Toujeo SolostarInsulin Glargine,hum.Rec.Anlog | 52 | $43,990 |
| FarxigaDapagliflozin Propanediol | 41 | $35,128 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 28 | $28,375 |
| EliquisApixaban | 30 | $26,688 |
| XareltoRivaroxaban | 15 | $24,012 |
| Breo ElliptaFluticasone/Vilanterol | 29 | $22,530 |
| JardianceEmpagliflozin | 20 | $19,819 |
| Repatha SureclickEvolocumab | 11 | $6,180 |
| Celecoxib | 115 | $4,733 |
| Rosuvastatin Calcium | 251 | $3,687 |
| Atorvastatin Calcium | 317 | $3,103 |
| Irbesartan | 130 | $2,548 |
| Ezetimibe | 49 | $2,431 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| GSKTrelegy Ellipta, Breo Ellipta | $310 | $50,90557 claims |
| Lilly USA, LLCMounjaro | $872 | $50,76949 claims |
| Novo NordiskOzempic | $566 | $46,95341 claims |
| AstraZenecaFarxiga | $2,930 | $35,12841 claims |
| PfizerEliquis | $253 | $26,68830 claims |
| Johnson & JohnsonXarelto | $456 | $24,01215 claims |
| Boehringer IngelheimJardiance | $842 | $19,81920 claims |
| AbbVieSynthroid | $988 | $1,20031 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 5,182 internal medicine providers in Illinois.
Other internal medicine in Libertyville
- David ReckerLibertyville$868K
- Dennis LevinsonChicago$25.3M
- Mary BrownRockford$16M
- Andrew BartlettChampaign$4.1M
- Danny SugimotoChicago$4M
- Peter O DonnellChicago$3.9M
- Daniel CatenacciChicago$3.5M
- Jeffrey GeohasEvanston$2.3M
- Patricia WalshChicago$2.1M
- Merle DiamondChicago$1.7M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.